OFF-THE-SHELF CD33 CAR-NK CELL THERAPY FOR RELAPSE/REFRACTORY AML: FIRST-IN-HUMAN, PHASE I TRIAL

Author(s): Ruihao Huang, Qin Wen, Xiaopi Wang, Hongju Yan, Yingying Ma, Maihong Wang, Xiao Han, Li Gao, Lei Gao, Cheng Zhang, Xi Zhang

(Abstract release date: 05/12/22) EHA Library. Huang R. 06/10/22; 356997; S133

Background
The primary results of CAR-T therapy for patients with R/R AML has shown limited efficacy and severe side-effect. One of the main challenges is that current targets for myeloid malignancies are either widely expressed on healthy hemopoietic stem cells such as CD33 or specific for a group of tumor cells presented as Lewis Y antigen, which could cause lasting bone marrow depression induced by “on target off tumor” side-effect or target negative relapse. Therefore, to receive a balance, we designed a CD33 CAR to recognize AML cells and using NK cells to replace T cells as the carrier to eliminate tumor cells. The CD33 CAR NK cells have combined the wide-expression advantage of CD33 target and the safety of NK cells.

Aims
To evaluate the safety and primary efficacy of CD33 CAR NK cells

Methods
5 qualified subjects with R/R AML aged between 18 and 65 years-old were enrolled and received round(s) of infusion of anti-CD33 CAR NK cells (6×10^8, 1.2×10^9 or 1.8×10^9 cells per round after the precondition with Fludarabine (30mg/m^2) and Cytoxan 300-500mg/m^2 for 3 days to 5 days, determined by tumor burden at baseline. We investigated the response rate at D28 and treatment related side-effect after the CAR NK cell infusion and the long-term efficacy.

Results
As of data cut (February 26, 2021), 5 pts have finished CAR NK cells infusion. The median age was 43 (18-65) years-old and the median tumor burden before infusion is 31% (21%-77.5%). 4 of 5 patients have received MRD negative CR at day 28 assessment. In dose group one, three patients have received 3 rounds of CAR NK cells (6×10^8, 1.2×10^9 and 1.8×10^9 cells) with the interval of 7 days after last round, and only patient 1 developed grade 1 CRS represented as fever after the infusion of 1.8×10^9 CAR NK cells and alleviated within 24h after symptomatic treatment. Patient 1 and patient 2 received MRD negative CR at day 14 and 21, but patient 2 relapsed at day 43 after first round infusion. In dosage group 2, patient 4 and patient 5 both received one dose of 1.8 ×10^9 cells CD33 CAR NK cells after precondition, patient 5 developed grade 2 CRS presenting as lasting fever for 6 days after infusion and alleviated after 5mg
Dexamethasone I.V., both patient 4 and patient 5 received MRD negative CR at day 28 after infusion. At the time of this abstract being uploaded, three patients remain MRD negative CR.

Conclusion
Our primary data of the phase I trial have proved the primary efficacy and safety of CD33 CAR NK cells for patients with R/R AML. The efficacy needs expanded samples and longer follow up.

Keyword(s): Acute myeloid leukemia, CAR-T, Refractory